- Select a blog category
By Mark Steedman, PhD. Manager Centre for Health Solutions
In the late 1970s, Earth, Wind & Fire released one of their biggest hits – September – with an opening line that has become an internet meme and is widely recognised around the world.
“Do you remember the 21st night of September?”
by Dr Francesca Properzi PhD
We are delighted to use this week’s blog to introduce the Centre’s new Research Manager, Francesca Properzi, who joined the team last week. Here is Francesca’s take on the way emerging technologies can improve pharma R&D.
R&D management in the pharmaceutical industry is facing unprecedented challenges. While the availability of new high-impact technologies has the potential to help reshape research and clinical development, our latest report from our Measuring the return from pharmaceutical innovation series, A new future for R&D?, shows the costs of drug development for 12 large cap pharma companies has increased sharply over the past eight years by nearly 50 per cent, totalling just under $2 billion per drug. Although a number of therapies are still expected to achieve blockbuster status, lower projected R&D returns are decreasing sharply from a once double digit high to an average of slightly over three per cent. This exceedingly low internal rate of return (IRR), is mostly due to companies paying the price of lower post-approval sales and increased R&D costs.
by Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte Consulting LLP
In July 2018, we released our report, Medtech and The Internet of Medical Things, which examined the proliferation of medical grade Internet of Things (IoT) technologies, the benefits they provide, the challenges that need to be overcome for them to become a staple in health care delivery and what the future of the medtech industry may look like. This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on some of the findings from the report, and the challenges and opportunities for Medtech in this rapidly evolving space.
by Pratik Avhad
India’s health care system is facing many challenges, including affordability, quality of care and access to services. India’s GDP per capita income is just $1,940, and out of pocket health care spending is almost 70 per cent, causing hardship for much of India’s population.1,2 In a systematic analysis of data from the Global Burden of Disease Study 2016, researchers ranked India’s quality of care and access as 145th out of 195 countries.3 However, with the fourth industrial revolution unfolding at pace, Pratik Avhad, the Centre’s India-based analyst, uses this week’s blog to explore whether artificial intelligence (AI) could be the answer to India’s quality and access challenges.
by Mark Steedman, PhD
Our colleagues in TMT (Technology, Media & Telecommunications) recently launched the results of their Mobile Readiness for Work 2018 survey of 3,369 workers across multiple industries in the UK. They examined how workers currently use technology and identify opportunities for using mobile devices and apps to improve workers’ productivity. Included in their survey results are responses from healthcare and social workers. This week’s blog explores the responses from healthcare and social workers in more detail, including comparing the responses to some of the insights from our report Time to care: Securing a future for the hospital workforce in the UK.
by Dawn Anderson, Managing Director, Deloitte Consulting LLP
The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials.
by Mark Steedman, PhD
This week’s blog is the second in a series focusing on eye health, which we are writing in advance of the launch of a global report on eye health at the November 2018 World Innovation Summit for Health (WISH). Our first blog in the series focused on glaucoma. This blog examines in more detail another leading cause of eye morbidity that affects millions of people around the world – age-related macular degeneration (AMD).
by Karen Taylor, Director, Centre for Health Solutions
In the three weeks since the NHS celebrated its 70th birthday, much has happened. From the appointment of a new Health Secretary, Matt Hancock MP, to the unravelling of the details of the national pay award. Meanwhile, hospital activity shows no let up and concerns over staffing and other resource shortages continue to build. This week’s blog provides my take on the Health Secretary’s maiden speech and its implications for the current health care system.
by Amen Sanghera, Analyst, UK Deloitte Centre for Health Solutions and Rui Zhou, Consultant, Deloitte Canada
Blockchain is increasingly touted as the technology that could transform many of the challenges facing healthcare and life sciences; whether it is providing secure and interoperable electronic health records (EHR), increasing the integrity of clinical trials data or improving the transparency of life science’s supply chain operations. While, the technology itself is not revolutionary, using it in the right situation, especially where trust, consensus or immutability are essential to the operations of the Life Science and Health care industries, could be transformational.
by Colin Terry, Partner, Deloitte Consulting
Following the launch of our eighth annual report ‘A new future for R&D? Measuring the return from pharmaceutical innovation 2017’, we hosted a peer-to-peer discussion on how R&D leaders can address R&D performance trends. The roundtable stimulated many insightful discussions among the senior R&D executives in attendance, and below are some of the key takeaways that resonated most with me.